Plataforma BIOBADASER III

Publicaciones

• After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries. Ann Rheum Dis. 2022 Sep 13:annrheumdis-2022-222835
  doi: 10.1136/ard-2022-222835
  Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, Lauper K, Mongin D, Iannone F, Pavelka K, Nordström DC, Inanc N, Codreanu C, Hyrich KL, Choquette D, Strangfeld A, Leeb BF, Rotar Z, Rodrigues A, Kristianslund EK, Kvien TK, Elkayam O, Lukina G, Bergstra SA, Finckh A, Courvoisier DS
  
• Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Musculoskeletal Care. 2022 Aug 22.
  doi: 10.1002/msc.1684
  Pombo-Suárez M, Seoane-Mato D, Díaz-González F, Cea-Calvo L, Sánchez-Alonso F, Sánchez-Jareño M, Jovani V, García-Magallón B, Martínez-González O, Campos-Fernández C, Manero J, Díaz-Torne C, Bohórquez C, Ros-Vilamajó I, Pérez-Vera Y, Castrejón I
  
• Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care & Research, 2022.
  doi: 10.1002/acr.24560
  Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ,Bjorn Gudbjornsson B,Catalin Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG,Carlos Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML
  
• Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration. Annals of the Rheumatic Diseases (2022).
  doi:10.1136/annrheumdis-2022-222586
  Lauper K, Ludici, M, Mongin D, Bergstra S A, Choquette D, Codreanu C, Cordtz R, De Cock C, Dreyer L, Elkayam O, Hauge EM, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L,Kristianslund EK, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Strangfeld A, Verschueren P, Courvoisier DS, Finckh A.
  
• The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis. Rheumatology. 2022.
  doi: 10.1093/rheumatology/keac174.
  Nissen M, Delcoigne B, Di Giuseppe D, Jacobsson L, Hetland ML, Ciurea A, Nekvindova L, Iannone F, Akkoc N, Sokka-Isler T, Fagerli KM, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, van der Horst-Bruinsma I, Loft AG, Möller B, Mann H, Conti F, Yildirim Cetin G, Relas H, Michelsen B, Ribeiro PA, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Askling J, Glintborg B, Lindström U.
  
• Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry. Rheumatology and Therapy, 2022:1-17.
  doi: 10.1007/s40744-022-00446-9.
  Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, Rodríguez-Lozano C, Pérez-Garcia C, Freire M, Campos C, Cáliz-Caliz R, Calvo J, Blanco-Madrigal JM, Pérez-Gómez A, Moreno-Martínez MJ, Linares L, Sánchez-Alonso F, Sastré C, Castrejón I.
  
• Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years. Scientific reports. 2021;11(1):15051.
  doi: 10.1038/s41598-021-94504-x.
  Sánchez-Piedra C, Sueiro-Delgado D, García-González J, Ros-Vilamajo I, Prior-Español A, Moreno-Ramos MJ, et al.
  
• Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry. Scientific reports. 2021;11(1):11091.
  doi: 10.1038/s41598-021-90442-w.
  Prior-Español A, Sánchez-Piedra C, Campos J, Manero FJ, Pérez-García C, Bohórquez C, et al.
  
• Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry. Musculoskeletal care. 2021.
  Epub 2021/10/21. doi: 10.1002/msc.1595. PubMed PMID: 34668303.
  Pombo-Suárez M, Sanchez-Piedra C, Ruiz-Montesino D, Diaz-Torne C, Jovaní V, Cea-Calvo L, et al.
  
• Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. Clinical rheumatology. 2021.
  Epub 2021/04/29. doi: 10.1007/s10067-021-05742-3. PubMed PMID: 33907904.
  Pombo-Suarez M, Sanchez-Piedra C, Garcia-Magallón B, Pérez-Gómez A, Manrique-Arija S, Martín-Doménech R, et al.
  
• Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. Arthritis care & research. 2021.
  Epub 2021/01/19. doi: 10.1002/acr.24560. PubMed PMID: 33460531.
  Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, et al.
  
• Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the rheumatic diseases. 2021:annrheumdis-2021-220097.
  doi: 10.1136/annrheumdis-2021-220097.
  Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, et al.
  
• European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response. Rheumatology (Oxford, England). 2021.
  Epub 2021/12/24. doi: 10.1093/rheumatology/keab945. PubMed PMID: 34940840.
  Christiansen SN, Ørnbjerg LM, Horskjær Rasmussen S, Loft AG, Askling J, Iannone F, et al.
  
• Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. Arthritis research & therapy. 2020;22(1):143.
  Epub 2020/06/17. doi: 10.1186/s13075-020-02231-x. PubMed PMID: 32539800.
  Vela P, Sanchez-Piedra C, Perez-Garcia C, Castro-Villegas MC, Freire M, Mateo L, et al
  
• Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the rheumatic diseases. 2020;79(7):988-90. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the rheumatic diseases. 2020;79(7):988-90.
  Epub 2020/06/07. doi: 10.1136/annrheumdis-2020-217948. PubMed PMID: 32503857; PubMed Central PMCID: PMCPMC7307213.
  Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, et al.
  
• Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology (Oxford, England). 2020;59(9):2455-61.
  Epub 2020/01/22. doi: 10.1093/rheumatology/kez656. PubMed PMID: 31960053.
  Michelsen B, Ørnbjerg LM, Kvien TK, Pavelka K, Nissen MJ, Nordström D, et al.
  
• Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD open. 2020;6(3).
  Epub 2020/09/21. doi: 10.1136/rmdopen-2020-001280. PubMed PMID: 32950963.
  Michelsen B, Lindström U, Codreanu C, Ciurea A, Zavada J, Loft AG, et al.
  
• The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford, England). 2020.
  Epub 2020/08/19. doi: 10.1093/rheumatology/keaa393. PubMed PMID: 32810263.
  Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, et al.
  
• Objectives and methodology of BIOBADASER phase iii. Reumatologia clinica. 2019;15(4):229-36.
  Epub 2017/09/25. doi: 10.1016/j.reuma.2017.08.001. PubMed PMID: 28935290.
  Sanchez-Piedra C, Hernández Miguel MV, Manero J, Roselló R, Sánchez-Costa JT, Rodríguez-Lozano C, et al.
  
• Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Annals of the rheumatic diseases. 2019;78(11):1536-44.
  Epub 2019/08/23. doi: 10.1136/annrheumdis-2019-215427. PubMed PMID: 31431486.
  Ørnbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, et al.
  
• Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology (Oxford, England). 2019;58(12):2221-9.
  Epub 2019/06/19. doi: 10.1093/rheumatology/kez221. PubMed PMID: 31209481.
  Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK, et al.
  
• Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatology international. 2019;39(3):509-15.
  Epub 2018/10/26. doi: 10.1007/s00296-018-4177-z. PubMed PMID: 30353269.
  Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C, et al
  
• Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford, England). 2019.
  Epub 2019/10/31. doi: 10.1093/rheumatology/kez427. PubMed PMID: 31665497.
  Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, et al.
  
• Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Annals of the rheumatic diseases. 2018;77(9):1276-82.
  Epub 2018/05/08. doi: 10.1136/annrheumdis-2017-212845. PubMed PMID: 29730637.
  Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, et al.
  
• Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD open. 2018;4(2):e000809.
  Epub 2018/11/30. doi: 10.1136/rmdopen-2018-000809. PubMed PMID: 30488002; PubMed Central PMCID: PMCPMC6241977.
  Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D, et al.
  
• Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER. Arthritis research & therapy. 2018;20(1):227.
  Epub 2018/10/12. doi: 10.1186/s13075-018-1728-3. PubMed PMID: 30305158; PubMed Central PMCID: PMCPMC6235210.
  Bethencourt Baute JJ, Sanchez-Piedra C, Ruiz-Montesinos D, Medrano San Ildefonso M, Rodriguez-Lozano C, Perez-Pampin E, et al.
  
• Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the rheumatic diseases. 2017;76(12):2025-30.
  Epub 2017/08/22. doi: 10.1136/annrheumdis-2017-211623. PubMed PMID: 28822981; PubMed Central PMCID: PMCPMC5705847.
  Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, et al.
  
• Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clinical rheumatology. 2017;36(4):773-9.
  Epub 2016/12/15. doi: 10.1007/s10067-016-3505-5. PubMed PMID: 27966068.
  Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, et al.
  
• Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. The British journal of dermatology. 2017;176(3):643-9.
  Epub 2016/06/04. doi: 10.1111/bjd.14776. PubMed PMID: 27258623.
  García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D.
  
• Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. Arthritis & rheumatology (Hoboken, NJ). 2016;68(6):1346-52.
  Epub 2016/01/28. doi: 10.1002/art.39595. PubMed PMID: 26815727.
  Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, et al.
  
• Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Annals of the rheumatic diseases. 2016;75(7):1336-42.
  Epub 2015/09/17. doi: 10.1136/annrheumdis-2015-207760. PubMed PMID: 26374404; PubMed Central PMCID: PMCPMC4941183.
  
  
• Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. EBioMedicine. 2016;11:302-6.
  Epub 2016/08/26. doi: 10.1016/j.ebiom.2016.08.024. PubMed PMID: 27558858; PubMed Central PMCID: PMCPMC5049989.
  Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, et al.
  
• Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis research & therapy. 2016;18:50.
  Epub 2016/02/18. doi: 10.1186/s13075-016-0951-z. PubMed PMID: 26883119; PubMed Central PMCID: PMCPMC4756505.
  Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al.
  
• The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD open. 2015;1(1):e000040.
  Epub 2015/10/29. doi: 10.1136/rmdopen-2014-000040. PubMed PMID: 26509062; PubMed Central PMCID: PMCPMC4613166.
  Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, et al.
  
• The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
  
  Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C
  
• BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries
  
  Carmona L, de la Vega M, Ranza R, Casado G, Titton DC, Descalzo MÁ, Gómez-Reino J
  
• Safety of biological therapies: New data from BIOBADASER.
  Reumatologia Clinica. 2010;6(SUPPL.)
  Rodriguez Lozano C.
  
• Dermatologicals manifestations induced by tumor necrosis factor antagonists therapy in rheumatic diseases. Incidence rate in BIOBADASER 2.0 registry.
  Arthritis and Rheumatism. 2011;63(10).
  Miguel MVH, Descalzo MA, Carmona L, Meineri M, Cabrera S, Caballero MEG, et al.
  
• Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis
  JAMA - Journal of the American Medical Association. 2012;308(9):898-908.
  Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al
  
• Infections in patients with rheumatic diseases treated with TNF antagonists
  Current Pharmaceutical Biotechnology. 2012;13(8):1418-25
  Pérez-Zafrilla B, Carmona L, Gómez-Reino JJ
  
• When can biological therapy be resumed in patients with rheumatic conditions who develop tuberculosis infection during tumour necrosis factors antagonists therapy? study based on the biobadaser data registry
  Arthritis and Rheumatism. 2012;64:S701
  Hernandez MV, Descalzo MA, Canete JD, Sanmarti R
  
• Systematic review: Safety and efficacy of anti-TNF in elderly patients. Revisión sistemática: eficacia y seguridad del tratamiento anti-TNF en pacientes ancianos
  Reumatol Clin. 2011;7(2):104-12
  Busquets N, Carmona L, Surís X
  
• Biobadaser 2.0: Analysis and trends in 2009
  Reumatologia Clinica. 2010;6(5):240-3
  Descalzo MT, Carmona L.
  
• Anti-TNF therapy and cancer.
  Reumatol Clin. 2010;6(2):102-5
  Carmona L.
  
• Update of BIOBADASER
  Reumatol Clin. 2009;5S1:66-70.
  Carmona L.
  
• Adverse reactions related to the administration of TNF inhibitors. Analysis of a registry of biologic therapy
  Reumatologia Clinica. 2008;4(3):90-5.
  Perez-Zafrilla B, Descalzo MA, Carmona L, Sellas A, Rodriguez B, Barcelo M, et al.
  
• Spanish registry for adverse events of biological therapy in rheumatic diseases (BIOBADASER): State report, January 26th, 2006
  Reumatologia Clinica. 2007;3(1):4-20.
  Descalzo MA, Montero D, Erra A, Marsal S, Fernandez Castro M, Mulero J, et al.
  
• Spanish registry of adverse events of biological therapies in rheumatic diseases (BIOBADASER): report as of january 14, 2005
  Reumatol Clin. 2005;1(2):95-111
  Carmona L, Gomez-Reino J, Gonzalez-Gonzalez R.
  
• Incidence of adverse events in patients with rheumatoid arthritis and spondyloarthritis exposed to anti-TNF therapy. Data from the brazilian registry for monitoring of biologic therapies in rheumatic diseases (biobadabrasil)
  Arthritis and Rheumatism. 2013;65:S1010.
  Ranza R, Titton DC, Vallim V, Silveira I, Ranzolin A, Hayata A, et al.
  
• Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0
  Rheumatol Int. 2014:1-9.
  Cobo-Ibáñez T, Descalzo M, Loza-Santamaría E, Carmona L, Muñoz-Fernández S.
  
• Differences in abatacept use in rheumatoid arthritis patients across europe: A pan-european database analysis of abatacept in european ra registries
  Arthritis and Rheumatism. 2013;65:S1248-S9.
  Neto D, Finckh A, Iannone F, Loza E, Lie E, Van Riel PLC, et al.
  
• Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: Study using the spanish registry of adverse events of biological therapies in rheumatic diseases.
  Arthritis Care and Research. 2
  Hernandez MV, Sanmarti R, Canete JD, Descalzo MA, Alsina M, Carmona L, et al.
  
• Safety profile of biological intravenous therapy in a rheumatoid arthritis patients cohort.
  Clinical nursing monitoring (Sebiol study). Reumatol Clin. 2013;9(2):80-4.
  Corominas H, Sanchez-Eslava L, Garcia G, Padro I, Aimarich C, Gonzalez J, et al.
  
• Lesiones cutáneas y terapia biológica con antagonistas del factor de necrosis tumoral
  Reumatol Clin. 2013 Jan-Feb; 9(1):53-61
  Hernández MV, Meineri M, Sanmartí R
  Descargar documento
• Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review.
  Semin Arthritis Rheum. 2012 Aug;42(1):89-103.
  Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L; BIOBADASER 2.0 Study Group.
  Descargar documento
• Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.
  Ann Rheum Dis. 2012 Mar;71(3):382-5
  Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C, Montoro M, Descalzo MA, Carmona L; BIOBADASER 2.0 Study Group.
  Descargar documento
• Safety of biological therapies: new data from BIOBADASER
  Reumatol Clin. 2011 Mar;6S3:S1-6
  Rodriguez Lozano C.
  Descargar documento
• Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.
  Rheumatology (Oxford). 2011 Nov;50(11):1999-2004. Epub 2011 Aug 19.
  Busquets N, Tomero E, Descalzo MÁ, Ponce A, Ortiz-Santamaría V, Surís X, Carmona L, Gómez-Reino JJ; BIOBADASER 2.0 Study Group.
  Descargar documento
• Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.
  Ann Rheum Dis. 2011 Oct 13. [Epub ahead of print]
  Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MA, Carmona L; on behalf of the BIOBADASER 2.0 Study Group.
  Descargar documento
• Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry
  Med Clin (Barc). 2011 Nov 12;137(12):533-40. Epub 2011 Apr 22.. [Epub ahead of print]
  Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ; BIOBADASER Study Group
  Descargar documento
• Biobadaser 2.0: análisis y tendencias en 2009
  Reumatol Clin, 2010; 6:240-3
  Descalzo MA, Carmona L, Grupo de estudio BIOBADASER
  Descargar documento
• Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review
  Semin Arthritis Rheum. 2011 Dec;41(3):524-33.Feb;40(4):330-7
  Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, Carmona L; BIOBADASER Study Group
  Descargar documento
• A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries
  Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1.
  Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A
  Descargar documento
• Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
  Rheumatology (Oxford), 2011 Jan;50(1):85-92
  Carmona L, Descalzo MA, Ruiz-Montesinos D, Manero-Ruiz FJ, Perez-Pampin E, Gomez-Reino JJ, BIOBADASER 2.0 study group
  Descargar documento
• Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
  Ann Rheum Dis, 2010 Oct; 69 (10): 1751-5
  García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ, Carmona L; BIOBADASER 2.0 Study Group
  Descargar documento
• Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy
  Clin Exp Rheumatol 2009; 27(6):920-925
  Peña-Sagredo JL, Fariñas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibañez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernández MV, Rodríguez-Gómez M, Maíz O, López R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA; BIOBADASER and EMECAR Groups
  Descargar documento
• Actualización de BIOBADASER
  Reumatol Clin 2009; 05(Suppl 1):66-70
  Carmona L
  Descargar documento
• Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience
  Clin Exp Rheumatol, 2008 Sep-Oct;26(5):854-9
  Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Fariñas MC; Biobadaser group
  Descargar documento
• Reacciones adversas relacionadas con la administración de los inhibidores del TNF. Análisis de un registro de terapias biológicas. BIOBADASER
  Reumatol Clin. 2008;4(3):90-5
  Pérez-Zafrilla B, Descalzo MA, Carmona L, Grupo de estudio BIOBADASER.
  Descargar documento
• Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
  Arthritis Rheum, 2007;57(5):756-61
  Gomez-Reino JJ, Carmona L, Descalzo MA, Biobadaser Group.
  Descargar documento
• Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): informe de la situación, 26 de enero de 2006.
  Reumatol Clin. 2007;3(1):4-20
  Descalzo MA. Comité científico de BIOBADASER y Grupo de estudio de BIOBADASER.
  Descargar documento
• All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists.
  Ann Rheum Dis. 2007 Feb 26;
  Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo Ibanez T, Gomez-Reino JJ, Study Groups EB.
  Descargar documento
• Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
  Acta Reumatol Port. 2006;31(3);201-3
  Gómez-Reino JJ, Carmona L.
  Descargar documento
• Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.
  Arthritis Res Ther 2006 Apr 18;8(3):R72
  Carmona L, Gomez-Reino JJ, BIOBADASER Group.
  Descargar documento
• Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
  Arthritis Res Ther 2006; 8:R29
  Gomez-Reino JJ, Carmona L, BIOBADASER Group.
  Descargar documento
• Spondyloarthritis in BIOBADASER. Las espondilartritis en BIOBADASER
  Reumatol Clin 2005; 1(Suppl 1): S12-5.
  L Carmona, R González.
  Descargar documento
• Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
  Arthritis Rheum 2005; 52(6):1766-72
  L Carmona, JJ Gómez-Reino, V Rodríguez-Valverde, MD Montero, E Pascual-Gómez, E Martin Mola, L Carreño, M Figueroa, BIOBADASER Group.
  Descargar documento
• Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de situación a 14 de enero de 2005.
  Reumatol Clin 2005; 1(2):95-111
  L Carmona, JJ Gómez-Reino, R González, Grupo de Estudio BIOBADASER.
  Descargar documento
• BIOBADASER: Informe de situación semestral.
  Rev Esp Reumatol 2004; 31(8)479-91
  Comité Científico de BIOBADASER.
  Descargar documento
• Registro de acontecimientos adversos de terapias biológicas en enfermedades reumáticas: BIOBADASER.
  Rev Esp Reumatol 2004 :31(4):210-3
  Carmona L.
  Descargar documento
• Treatment of rheumatoid arthritis with TNF inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report.
  Arthritis Rheum 2003; 48(8):2122-7
  Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Comité Científico de BIOBADASER.
  Descargar documento
• Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists
  Semin Arthritis Rheum, 2011 Aug;41(1):71-80
  Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, Gomez-Reino JJ; BIOBADASER Study Group; EMECAR Study Group
  Descargar documento
• BIOBADASER: Informe de situación semestral.
  Rev Esp Reumatol 2003; 30(10)554-64
  Comité Científico de BIOBADASER.
  Descargar documento
• BIOBADASER: Informe de situación semestral.
  Rev Esp Reumatol 2003;30(3):119-23
  Comité Científico de BIOBADASER.
  Descargar documento
• BIOBADASER: Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas.
  Rev Esp Reumatol 2002;29(6):292-299
  Comité Científico de BIOBADASER.
  Descargar documento